Evidence map›Paper›PMID 41347080›Full record

ReviewFrontiers in oncology2025

Extracellular derived-exosomal micrornas in pancreatic cancer: investigating their diagnostic importance and potential targets for the prevention and treatment in pancreatic cancer.

Rashid Mir, Ulfat Jan, Jameel Barnawi, Naseh A Algehainy, Mohammed M Jalal, Malik A Altayar, Reema M Almotairi, Tarig Ms Alnour, Syed Khalid Mustafa, Abdulaziz S Al-Otaibi and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rashid MirPrince Fahad Bin Sultan Chair for Biomedical Research, University of Tabuk, Tabuk, Saudi Arabia.
Ulfat JanGenome diversity unit, University of Tabuk, Tabuk, Saudi Arabia.
Jameel BarnawiDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Naseh A AlgehainyPrince Fahad Bin Sultan Chair for Biomedical Research, University of Tabuk, Tabuk, Saudi Arabia.
Mohammed M JalalDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Malik A AltayarDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Reema M AlmotairiPrince Fahad Bin Sultan Chair for Biomedical Research, University of Tabuk, Tabuk, Saudi Arabia.
Tarig Ms AlnourPrince Fahad Bin Sultan Chair for Biomedical Research, University of Tabuk, Tabuk, Saudi Arabia.
Syed Khalid MustafaDepartment of Chemistry, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.
Abdulaziz S Al-OtaibiDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Adel D AlthaqafyDepartment of Chemistry, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.
Elham M AlhathliFaculty of Nursing, University of Taif, Taif, Saudi Arabia.
Salma AlrdaheDepartment of Biology, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.
Mohammad Muzaffar MirDepartment of Clinical Biochemistry, College of Medicine, University of Bisha, Bisha, Saudi Arabia.
Nada Zaki SageerKing Faisal Special Hospital, MOH, Makkah, Saudi Arabia.
Abdullatif Taha BabakrDepartment of medical biochemistry, Faculty of medicine, Umm al-Qura University, Makkah, Saudi Arabia.
Afaq Ahmad KhanDepartment of Clinical Haematology, Sher-I -Kashmir Institute of Medical Sciences, Soura, Jammu & Kashmir, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer stands out as a deadly disease because patients receive late diagnosis and struggle with ineffective treatments. Exosomal microRNAs (miRNAs) that exist inside lipid bilayers help tumors grow and spread while making cells resistant to treatment and enabling cell-to-cell communication. Their ability to stay stable in body fluids makes them good candidates for early disease detection and treatment prediction tests. Research shows that miR-21, miR-17-5p, and miR-155 exosomal miRNAs help pancreatic cancer progress but also provide new targets for medical treatment. This review consolidates current evidence on the diagnostic, prognostic, and therapeutic potential of exosomal miRNAs in pancreatic cancer, integrating mechanistic insights into key signaling pathways such as PTEN/PI3Kγ, KRAS/MAPK, and TGF-β. Compared with previous reports, this work provides a comparative framework linking disease-specific exomiR profiles to other cancers, highlighting miR-21, miR-17-5p, miR-155, and miR-301a as central modulators. We further discuss methodological challenges, translational opportunities, and future directions in developing exosome-based diagnostics and miRNA-loaded therapeutic platforms. Understanding exosomal miRNA networks can pave the way for precision detection and targeted therapy in pancreatic cancer.

Indexed as

biomarkersdiagnosisexosomal microRNAspancreatic cancerprognosis

Identifiers

PMID41347080
PMCPMC12672277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.